<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41986">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02071524</url>
  </required_header>
  <id_info>
    <org_study_id>22012014</org_study_id>
    <nct_id>NCT02071524</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effects of Fluid Therapy on Respiratory Mechanics</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Ferrara</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that large doses of fluids used during intraoperative could
      affect lung parenchyma structure and, consequently, gas exchange and respiratory mechanics.
      The purpose of this study  is to evaluate fluids effects on oxygenation, respiratory
      mechanics, by using two different solutions: crystalloid or colloid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:

        -  patients undergoing elective abdominal, thoracic, vascular surgery

        -  minimum age 18 years

        -  informed consent

      Exclusion Criteria:

        -  patients with severe cardiomyopathy or severe heart failure

        -  history of coagulation disorders

        -  patients with severe cardiovascular or respiratory disorders

        -  renal insufficiency

      Respiratory mechanic parameters (i.e., inspiratory peak pressure, plateau pressure, total
      airway resistance, and static compliance) are obtained .Blood samples are drawn
      simultaneously from the arterial catheters for gas analysis. Data were collected after
      induction of anesthesia (T0) after 1 h (T1), 2 h (T2),  3 h (T3) and at  the end of surgery.

      Primary outcome: evaluate the  fluids effects on oxygenation, respiratory mechanics

      Secondary outcome: Incidence of surgery related complications
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>effects on oxygenation, respiratory mechanics</measure>
    <time_frame>every 30 minutes till the end of surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Lung compliance (l/cmH20), Airaway resistance (cmH2O/L/sec) and PaO2 will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of respiratory complications</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Complications like acute respiratory failure, pneumonia and ARDS will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mechanical Ventilation Complication</condition>
  <condition>Actual Impaired Fluid Volume</condition>
  <arm_group>
    <arm_group_label>Cristalloid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group cristalloid (ringer lactate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>colloids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>colloid: cristalloid in according to cardiac output</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group Colloid</intervention_name>
    <description>Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)</description>
    <arm_group_label>colloids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cristalloid administration</intervention_name>
    <description>Only Ringer Lactate administration</description>
    <arm_group_label>Cristalloid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing elective abdominal, thoracic, vascular surgery

          -  minimum age 18 years

          -  informed consent

        Exclusion Criteria:

          -  patients with severe cardiomyopathy or severe heart failure

          -  history of coagulation disorders

          -  patients with severe cardiovascular or respiratory disorders

          -  renal insufficiency

          -  severe liver diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Savino Spadaro, researcher</last_name>
    <phone>+390532206570</phone>
    <email>spdsvn@unife.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo A Volta, professor</last_name>
      <phone>+390532206570</phone>
      <email>vlc@unife.it</email>
    </contact>
    <investigator>
      <last_name>Savino Spadaro, Researcher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 21, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Ferrara</investigator_affiliation>
    <investigator_full_name>Savino Spadaro</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
